EP1947108A1 — TGR5 modulators and methods of use thereof
Assigned to Intercept Pharmaceuticals Inc · Expires 2008-07-23 · 18y expired
What this patent protects
The invention relates to compounds of Formula I: or a pharmaceutically effective salt, solvate, hydrate, or prodrug thereof, wherein: R 1 is hydrogen, hydroxy, or halogen; R 2 is hydrogen or α-hydroxy; R 3 is hydroxy, NH(CH 2 ) m SO 3 H, or NH(CH 2 ) n CO 2 H; R 4 is hy…
USPTO Abstract
The invention relates to compounds of Formula I: or a pharmaceutically effective salt, solvate, hydrate, or prodrug thereof, wherein: R 1 is hydrogen, hydroxy, or halogen; R 2 is hydrogen or α-hydroxy; R 3 is hydroxy, NH(CH 2 ) m SO 3 H, or NH(CH 2 ) n CO 2 H; R 4 is hydrogen, alkyl, or halogen; R 5 is unsubstituted or substituted alkyl, or aryl; R 6 is hydrogen or R 5 and R 6 taken together with the carbons to which they are attached form a ring of size 3, 4, 5, or 6 atoms; m is an integer 0, 1, 2, 3, 4, or 5, and n is an integer 0, 1, 2, 3, 4, or 5. The compounds of Formula I are TGR5 modulators useful for the treatment of various diseases.
Drugs covered by this patent
- Ocaliva (OBETICHOLIC ACID) · Intercept Pharms Inc
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.